Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Bronchodilators Face Near Extinction Under FDA Proposal – Trade Group

This article was originally published in The Tan Sheet

Executive Summary

FDA's proposal to reclassify OTC ephedrine combination products as Category II would effectively remove ephedrine bronchodilators from the consumer marketplace, according to comments recently submitted to the agency by an industry trade group

You may also be interested in...



DEA Proposes Registration Fee Increases To Fund Diversion Control Program

Non-retail distributors of pseudoephedrine, phenylpropanolamine and combination ephedrine products would be required to pay the full amount of Drug Enforcement Administration registration fees, under a proposed rule published in the Federal Register Nov. 16

FDA-Proposed Warning For OTC Bronchodilators “Alarming” – Wyeth

FDA should re-word a cardiovascular warning statement it has proposed for OTC bronchodilator products because the statement is "unnecessarily alarming" and "goes beyond that which is supported by data," Wyeth Consumer Healthcare maintains

OTC Bronchodilators With Ephedrine Permitted In New Proposed Rule

Additional warnings and other revised labeling would be required for bronchodilator products containing ephedrine or epinephrine under an FDA proposed rule published in the July 13 Federal Register

Topics

UsernamePublicRestriction

Register

LL1129552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel